losartan-potassium and hexamethylene-bisacetamide

Hexamethylenebisacetamide (HMBA) is a potent differentiation inducer of murine erythroleukemia cells. Immunoprecipitation followed by Western blotting with an anti-phosphotyrosine (P-Tyr) antibody revealed that HMBA increased P-Tyr levels and/or amounts of several proteins containing P-Tyr in F5-5, a murine erythroleukemia cell line. Among these proteins, we identified a Mr 130,000 protein to be Janus-activated kinase 2 (JAK2). HMBA induced tyrosine phosphorylation of JAK2 and signal transducers and activators of transcription 5 (STAT5) but not other JAKs or STATs. This phosphorylation was apparent 12 h after treatment, maximal at 24 h, and persisted for at least 96 h. Consistently, HMBA increased STAT5 DNA-binding activities. Other chemical inducers, DMSO and butyrate, also induced a sustained activation of JAK2/STAT5, whereas fetal calf serum and erythropoietin induced transient activation but not differentiation. Furthermore, overexpression of a dominant-negative form of STAT5 inhibited the chemically induced differentiation. These results suggest that persistent activation of the signaling pathway plays a significant role in the inducer-mediated differentiation. Our data also suggest that molecular mechanisms for the inducer-mediated activation of JAK2 are independent of cytokine receptor-mediated activation mechanisms. We tentatively conclude that cytokine signaling is an important target of chemical inducers in these cells.

Topics: Acetamides; Animals; Antineoplastic Agents; Cattle; Cell Differentiation; Cytokines; DNA-Binding Proteins; DNA, Neoplasm; Erythropoietin; Fetal Blood; Friend murine leukemia virus; Janus Kinase 2; Leukemia, Erythroblastic, Acute; Mice; Milk Proteins; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Signal Transduction; STAT5 Transcription Factor; Trans-Activators; Tumor Cells, Cultured

The erythroid-potentiating activity (EPA) of the tissue inhibitor of metalloproteinase-1 (TIMP-1) was re-examined using ELM-I-1-3, a mouse erythroleukemia cell line, which responded well to erythropoietin. Depletion of pre-existing TIMP-1 from fetal calf serum in culture medium using monoclonal antibody suppressed erythropoietin-induced differentiation as measured by the induction of hemoglobin, commitment assay and globin mRNAs. The removal of TIMP-1 also suppressed the proliferation of ELM-I-1-3 as measured by cell number and de novo DNA synthesis. These changes were reversed by the addition of purified TIMP-1 to the culture medium. Anti-TIMP-1 antibody also blocked both hexamethylene bisacetamide (HMBA)-induced erythroid differentiation and the proliferation of both ELM-I-1-3 and Friend erythroleukemia cells. Considering previous reports analyzing the chemical induction of Friend mouse erythroleukemia cell differentiation, our results suggest that erythropoietin- or HMBA-induced erythroid differentiation might also be coupled with cell proliferation. Our 3H thymidine-uptake experiment shows that TIMP-1 removal was also effective in the inhibition of cell growth of various other cell lines in addition to erythroleukemia cell lines. These results suggest that EPA action of TIMP-1 on erythroid leukemia cell lines is closely related to its activity to promote the cell growth of various cell lines and cells including erythroleukemia cell lines.

Topics: Acetamides; Animals; Antibodies; Cell Differentiation; Cell Division; DNA, Neoplasm; Erythroid Precursor Cells; Erythropoietin; Friend murine leukemia virus; Gene Expression; Globins; Glycoproteins; Humans; Leukemia, Erythroblastic, Acute; Mice; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured